This site is intended for healthcare professionals

Dupixent significantly reduced severe asthma attacks in children

and is the only biologic to demonstrate improvement in children’s lung function in a randomized Phase III trial.- Sanofi + Regeneron
Read time: 2 mins
Last updated:16th Mar 2021
Published:14th Oct 2020
A pivotal Phase III trial of Dupixent (dupilumab) met its primary and all key secondary endpoints in children aged 6 to 11 years with uncontrolled moderate-to-severe asthma.
Condition: Asthma
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest